NCT01360034

Brief Summary

The purpose of this study was to compare the effectiveness of nifedipine versus indomethacin as tocolytic for the treatment of preterm labour with short cervix (\< 2.5cms).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
216

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Dec 2015

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 25, 2011

Completed
4.5 years until next milestone

Study Start

First participant enrolled

December 1, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

January 5, 2015

Status Verified

January 1, 2015

Enrollment Period

5 months

First QC Date

May 20, 2011

Last Update Submit

January 1, 2015

Conditions

Keywords

Obstetric labor, prematureShort cervixNifedipineIndomethacin

Outcome Measures

Primary Outcomes (1)

  • Reduction of preterm birth (before 48 hours, allowing use of corticosteroids).

    36 months

Secondary Outcomes (2)

  • Reduction of preterm labour (before 35 weeks).

    48 months

  • Adverse effects

    48 months

Study Arms (2)

Nifedipine

EXPERIMENTAL

108 patients will receive nifedipine as tocolytic for 48 hours.

Drug: Nifedipine

Indomethacin

EXPERIMENTAL

108 patients will receive indomethacin as tocolytic for 48 hours.

Drug: Indomethacin

Interventions

Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.

Nifedipine

Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.

Indomethacin

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Pregnant women between 24 and 34 weeks of gestation.
  • Cervical length (determined by transvaginal ultrasound) of 2.5 cms or less

You may not qualify if:

  • All contraindications for tocolysis (fetal distress, abruptio placenta).
  • Multiple pregnancy.
  • All contraindications for the use of any of the two drugs (indomethacin or nifedipine).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saint Thomas Hospital

Panama City, Provincia de Panamá, Panama

Location

Related Publications (1)

  • Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.

MeSH Terms

Conditions

Obstetric Labor, Premature

Interventions

NifedipineIndomethacin

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

DihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Jorge Espinosa, Resident

    Saint Thomas Hospital, Panama

    PRINCIPAL INVESTIGATOR
  • Osvaldo Reyes, MD

    Saint Thomas Hospital, Panama

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jorge Espinosa, Resident

CONTACT

Osvaldo Reyes, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 20, 2011

First Posted

May 25, 2011

Study Start

December 1, 2015

Primary Completion

May 1, 2016

Study Completion

June 1, 2016

Last Updated

January 5, 2015

Record last verified: 2015-01

Locations